[BIOC] Biocept, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical Specialities

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 0.81 Change: 0.01 (0.97%)
Ext. hours: Change: 0 (0%)

chart BIOC

Refresh chart

Strongest Trends Summary For BIOC

BIOC is in the long-term down -96% below S&P in 11 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA tests utilizing a standard blood sample. The company?s tests provide information to oncologists that enable them to select the appropriate treatment for their patients based on detailed data on the characteristics of tumors. It offers OncoCEE-BR, a breast cancer CTC test that allows physician to characterize the tumor to help define treatment options. The company is also developing other OncoCEE CTC tests, including OncoCEE-LU for lung cancer; OncoCEE-GA for gastric cancer; OncoCEE-CR for colorectal cancer; OncoCEE-PR for prostate cancer; and OncoCEE-ME for melanoma. Biocept, Inc. sells its products through its direct sales force and partners that focus on selling directly to community oncologists in hospitals, cancer centers, and offices in the United States, as well as biopharma companies. It has collaboration agreement with Rosetta Genomics, Ltd. to evaluate microRNAs

Fundamental Ratios
Shares Outstanding EPS-1.65 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 689.47% Sales Growth - Q/Q97.37% P/E-0.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-69.57% ROE-107.05% ROI-80.02%
Current Ratio9.07 Quick Ratio8.98 Long Term Debt/Equity0.25 Debt Ratio0.16
Gross Margin-829.02% Operating Margin-5489.41% Net Profit Margin-5701.96% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities17.29 M Cash From Investing Activities-30 K Cash From Operating Activities-3.33 M Gross Profit-710 K
Net Profit-3.8 M Operating Profit-3.65 M Total Assets20.9 M Total Current Assets20.27 M
Total Current Liabilities2.23 M Total Debt130 K Total Liabilities7.32 M Total Revenue150 K
Technical Data
High 52 week10.8 Low 52 week0.28 Last close0.82 Last change1.25%
RSI35.25 Average true range0.06 Beta0.53 Volume88.26 K
Simple moving average 20 days-9.71% Simple moving average 50 days-20.38% Simple moving average 200 days-81.95%
Performance Data
Performance Week-10.07% Performance Month-19.61% Performance Quart-18.81% Performance Half-87.32%
Performance Year-6.82% Performance Year-to-date-83.09% Volatility daily3.09% Volatility weekly6.9%
Volatility monthly14.14% Volatility yearly48.98% Relative Volume119.54% Average Volume1.9 M
New High New Low

News

2020-05-29 08:30:00 | Data Affirming Biocept's Target Selector™ Platform Identifies Cancer Mutations in Cerebrospinal Fluid Presented at ASCO 2020 Virtual Scientific Program

2020-05-20 08:05:00 | Biocept to Participate in Maxim Group's COVID-19 Virtual Conference Series on May 27, 2020

2020-05-14 08:05:00 | Biocept Expands its Menu of Molecular Assay Kit Offering with Release of its Target Selector™ BRAF Kit for Clients' Use in Their Own Laboratories

2020-05-13 16:05:00 | Biocept Reports First Quarter 2020 Financial Results

2020-04-29 08:05:00 | Biocept to Release First Quarter 2020 Financial Results and Host Investor Conference Call on May 13, 2020

2020-04-28 08:05:00 | Biocept Announces CE-IVD Mark and Availability of its Target Selector™ EGFR Molecular Assay Kit in Europe

2020-04-20 08:05:00 | Biocept Launches Unique Line of Molecular Assay Kits for Detection of Key Oncogene Mutations Based on its Proprietary Target Selector™ Technology Validated for Use in Both Tissue and Blood Samples

2020-04-14 09:00:00 | Biocept Announces Pricing of $10.3 Million Registered Direct Offering Priced At-The-Market

2020-04-13 09:54:12 | Biocept To Begin COVID-19 Testing; BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics

2020-04-09 19:17:00 | Biocept to Begin COVID-19 Testing

2020-04-09 08:05:00 | Brazil Patent Granted for Biocept's Target Selector™ Oncogene Mutation Enrichment and Detection Platform

2020-04-02 08:05:00 | Australia Patent Issued for Primer-Switch Mutation Detection and Amplification Platform

2020-04-01 19:53:52 | For Penny Investors, Biocept Stock Makes a Good Speculative Play

2020-03-28 08:23:44 | US$1.00: That's What Analysts Think Biocept, Inc. NASDAQ:BIOC Is Worth After Its Latest Results

2020-03-26 08:05:00 | Biocept Enters into Laboratory Services Agreement with Second California-Based Independent Physician Association

2020-03-25 16:05:00 | Biocept Reports 2019 Fourth Quarter and Full Year Financial Results

2020-03-25 14:30:00 | Biocept, Inc. to Host Earnings Call

2020-03-18 08:30:00 | Biocept, Inc. Discusses Highlights for 2019, Recent News and What to Look Out For in Q2 2020 in New SNNLive Video Interview on SNN Network

2020-03-18 08:05:00 | Biocept to Release 2019 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 25, 2020

2020-03-11 09:23:47 | Biotech Maven Hal Mintz Snaps Up These 3 Small Biotech Stocks

2020-03-09 08:05:00 | Newly Published Data in Journal of Clinical Pathology Provides Clinical Validation for Biocept's Target Selector™ qPCR Assay to Identify Cancer-Associated Mutations

2020-03-05 08:30:00 | Biocept Announces Pricing of $6.6 Million Registered Direct Offering Priced At-The-Market

2020-03-02 10:48:00 | Biocept's stock plummets on heavy volume after share offering prices at deep discount

2020-03-02 10:48:00 | Biocept's stock plummets on heavy volume after share offering prices at deep discount

2020-03-02 08:30:00 | Biocept Announces Pricing of $9.2 Million Registered Direct Offering Priced At-The-Market

2020-02-14 08:05:00 | Biocept Appoints Cory J. Dunn Senior Vice President of Commercial Operations

2020-02-10 08:05:00 | Biocept Enters into Laboratory Services Agreement with California-Based Independent Physician Association

2020-02-04 08:05:00 | Biocept to Present at the 22nd Annual BIO CEO & Investor Conference

2020-01-14 08:05:00 | Biocept Announces Validation and Availability of its Liquid Biopsy Platform for the Detection of Actionable Cancer Biomarkers in Cerebrospinal Fluid

2020-01-12 08:22:24 | How Does Investing In Biocept, Inc. NASDAQ:BIOC Impact The Volatility Of Your Portfolio?

2020-01-08 09:00:00 | Biocept, Inc. Awarded United States Patent for the Use of Antibodies in Combination with Any Solid Surface to Detect Any Target Cell of Interest - from Any Sample Type

2019-12-12 08:00:00 | Biocept Announces Closing of $10.0 Million Underwritten Public Offering

2019-12-10 07:56:02 | The Daily Biotech Pulse: ASH Meeting Wraps, Fast Track Designation For Equillium, Pfizer To Buy $3M In ContraFect Shares

2019-12-09 09:15:00 | Biocept Announces Pricing of $10.0 Million Underwritten Public Offering

2019-12-03 08:05:00 | Biocept's Liquid Biopsy CTC Testing for Breast Cancer to Be Featured in Poster Presentation at the 2019 San Antonio Breast Cancer Symposium®

2019-11-21 08:05:00 | Biocept Announces the Launch of its Liquid Biopsy Test to Detect TRK Biomarkers in the Blood of Patients Diagnosed with Cancer

2019-11-13 16:05:00 | Biocept Reports Third Quarter 2019 Financial Results

2019-11-07 08:05:00 | Biocept Announces CE IVD Marks and Availability of its CEE-Sure® Blood Collection Tube and Sample Collection Shipping Kit in Europe

2019-11-06 08:05:00 | Biocept to Release Third Quarter 2019 Financial Results and Host Investor Conference Call on November 13, 2019

2019-11-04 08:05:00 | Biocept's Target Selector™ Tests and Kits to Be Featured in Six Poster Presentations at the 2019 Association for Molecular Pathology Annual Meeting

2019-10-14 10:05:49 | Why Biocept, Inc.'s NASDAQ:BIOC CEO Pay Matters To You

2019-10-07 08:05:00 | Biocept's Target Selector™ ctDNA Platform Demonstrates Single Copy Detection for EGFR, BRAF, and KRAS Mutations; Study Results Published in Peer-Reviewed Journal, PLOS ONE

2019-10-03 08:05:00 | Biocept Announces Issuance of South Korean Patent Covering its Target Selector™ Oncogene Mutation Enrichment and Detection Platform

2019-09-03 08:05:00 | Biocept to Present at Two Investment Conferences in September

2019-08-22 08:05:00 | High Sensitivity of Biocept's Target Selector™ Platform Using CEE-Sure™ Blood Collection Tubes to Be Featured in Poster Presentation at the 2019 IASLC World Conference on Lung Cancer

2019-08-13 08:05:00 | Biocept Receives Three Additional Patents Covering its Antibody and Microchannel Technology and Enhanced Detection of Cancer Cells

2019-08-12 16:05:00 | Biocept Reports Second Quarter 2019 Financial Results

2019-08-12 14:30:00 | Biocept, Inc. to Host Earnings Call

2019-08-05 08:05:00 | Biocept to Release Second Quarter 2019 Financial Results and Host Investor Conference Call on August 12, 2019

2019-07-22 08:05:00 | Biocept Announces Laboratory Services Provider Agreement with BeaconLBS®